Eli Lilly: Great Time To Divest Before It Potentially Crashes

seekingalpha05-04

Eli Lilly and Company delivered robust Q1 earnings, leading to an initial post-earnings surge in LLY stock.However, LLY has lost buying momentum, as selling intensity has overtaken Lilly's earnings ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432814440?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg","is_english":true,"pubTime":"2024-05-04 23:30","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2432814440","market":"hk","top_or_hot":-1,"title":"Eli Lilly: Great Time To Divest Before It Potentially Crashes","media":"seekingalpha","content":"<div>\n<p>Eli Lilly and Company delivered robust Q1 earnings, leading to an initial post-earnings surge in LLY stock.However, LLY has lost buying momentum, as selling intensity has overtaken Lilly's earnings ...</p>\n\n<a href=\"https://seekingalpha.com/article/4689405-eli-lilly-great-time-to-divest-before-it-potentially-crashes\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly: Great Time To Divest Before It Potentially Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly: Great Time To Divest Before It Potentially Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-04 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4689405-eli-lilly-great-time-to-divest-before-it-potentially-crashes><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly and Company delivered robust Q1 earnings, leading to an initial post-earnings surge in LLY stock.However, LLY has lost buying momentum, as selling intensity has overtaken Lilly's earnings ...</p>\n\n<a href=\"https://seekingalpha.com/article/4689405-eli-lilly-great-time-to-divest-before-it-potentially-crashes\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0256863811.USD","symbol_name":"ALLIANZ US EQUITY \"A\" INC","start_time":0,"source_url":"https://seekingalpha.com/article/4689405-eli-lilly-great-time-to-divest-before-it-potentially-crashes","article_id":"2432814440","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432814440","pubTimestamp":1714836600,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Eli Lilly and Company delivered robust Q1 earnings, leading to an initial post-earnings surge in LLY stock.However, LLY has lost buying momentum, as selling intensity has overtaken Lilly's earnings eu","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LLY":"礼来","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4588":"碎股","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","NVO":"诺和诺德","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4581":"高盛持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD"},"translate_title":"礼来公司：在它可能崩溃之前撤资的好时机","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":0.9},"content_text":"Eli Lilly and Company delivered robust Q1 earnings, leading to an initial post-earnings surge in LLY stock.However, LLY has lost buying momentum, as selling intensity has overtaken Lilly's earnings euphoria.Eli Lilly is still well-positioned to capture the market for weight loss drugs. However, its valuation bifurcation to Novo Nordisk stock is hard to justify.With LLY stock suffering from a post-earnings hangover, as sellers take profit, it's time to get out quickly.   jetcityimage Eli Lilly Raised Guidance Downplayed Fears Eli Lilly and Company (NYSE:LLY) investors have continued to jump onto the bandwagon as the leading biopharma company delivered its recent earnings. Accordingly, LLY surpassed Wall Street estimates at Eli Lilly's first-quarter earnings release. Eli Lilly management raised guidance for 2024, alleviating fears about extended supply constraints impacting the company's near-term revenue recognition. As a result, LLY buyers saw an opportunity to buy LLY's recent pullback as it fell into correction territory from its March 2024 highs. However, LLY's post-earnings fervor cooled as buying momentum quickly dissipated this week. Yesterday's weakness could be attributed to the recent news highlighting downward pricing adjustments affecting GLP-1 drugs. As a result, the market is likely assessing Lilly's execution and competitive risks on management's raised guidance.  Accordingly, Lilly delivered revenue of $8.77B in Q1, up 26% YoY. Lilly attributed the robust performance to higher prices (10% increase) and stronger volume actualization (16% increase). In addition, Lilly raised its revenue outlook by $2B for 2024 and improved its adjusted EPS outlook by $1.30, anticipating a midpoint metric of $13.75.  Therefore, I'm not surprised that LLY buyers delivered an initial post-earning surge, suggesting Lilly's supply constraints aren't expected to hamper its second-half production momentum. Management has also indicated that Lilly anticipates a more robust second-half performance as it navigates near-term headwinds to meet underlying demand.  Eli Lilly's Long-Term Roadmap Is Robust Investors in LLY are likely betting on the long-term secular growth thesis in weight loss drugs. Varying estimates on the GLP-1 TAM suggest it could reach $40B by 2029. Bloomberg's estimate indicates the market for obesity treatments could reach $80B by 2030. Peak sales are anticipated to be in the $100B range. NVO asserts leadership in GLP-1 sales, highlighting Novo Nordisk's global GLP-1 market share of 55.3%. Given the robust performance of NVO and LLY over the past year, I believe the market believes there are sufficient growth opportunities for Novo Nordisk and Lilly in the medium- and long term.  Eli Lilly Q1 revenue segments (Eli Lilly filings) Eli Lilly highlighted Mounjaro, Zepbound, Verzenio, and Jardiance as key revenue drivers in Q1. As seen above, Mounjaro and Zepbound were pivotal to Lilly's growth inflection, but Lilly is far from a one-product company. Therefore, the company has a solid product and development portfolio to assure LLY investors of Lilly's well-diversified portfolio and long-term growth outlook.  Moreover, Lilly management also provided insights to investors about Lilly's next-gen weight loss drugs, as an analyst on Eli Lilly's Q1 conference call noted \"development of around half a dozen candidates.\" Lilly management provided several key differentiating factors to deliver its value proposition. In addition, Eli Lilly underscored that its \"robust pipeline represents a multi-decade investment in treating abnormal metabolism and related diseases.\" Therefore, I concur that LLY seems to be a solid long-term bet for early investors, but not now, as LLY is still overvalued. But LLY Is Significantly Overvalued   LLY Quant Grades (Seeking Alpha) LLY is assigned an \"F\" valuation grade, which underscores its relative overvaluation to its peers in the healthcare sector. That's unsurprising, given LLY's tremendous performance with its GLP-1 drugs. Underpinned by a fundamentally strong business model (\"A+\" profitability grade), Lilly is well-positioned to justify its growth thesis at a less aggressive valuation. LLY Vs. NVO forward adjusted EBITDA multiples (TIKR) Moreover, the valuation bifurcation between LLY and NVO has surged to significant levels, behooving caution. Novo Nordisk is still the market leader and boasts a robust \"A-\" growth grade. Therefore, I assessed that the bifurcation seems unjustified, given that the optimism on NVO and LLY is mainly predicated on their dominance in the GLP-1 market. As a result, I believe LLY's relative overvaluation against its peers and NVO seems increasingly hard to justify. Is LLY Stock A Buy, Sell, Or Hold? LLY price chart (weekly, medium-term, adjusted for dividends) (TradingView) Accordingly, LLY suffered a pullback after its initial post-earnings surge, losing most of the gains made this week, as seen above.  The $800 resistance level has proved to be a robust take-profit zone for sellers, as they anticipated FOMO buyers rushing in as exit liquidity.  Therefore, the risk/reward for LLY is increasingly unattractive, with Eli Lilly needing to execute immaculately to justify its significant growth premium.  Healthcare investors who want to participate in the GLP-1 growth story through LLY should remain patient. The $600 zone remains a possible and less aggressive level to consider adding exposure. With LLY's selling resistance and relative overvaluation providing a fantastic opportunity for LLY investors to consider cutting exposure significantly, I maintain my Sell rating. Rating: Maintain Sell. Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Consider this article as supplementing your required research. Please always apply independent thinking. Note that the rating is not intended to time a specific entry/exit at the point of writing unless otherwise specified. I Want To Hear From You  Have constructive commentary to improve our thesis? Spotted a critical gap in our view? Saw something important that we didn’t? Agree or disagree? Comment below with the aim of helping everyone in the community to learn better!","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432814440"}